Compounds > 2-{4-[(2-aminophenyl)thio]-3-nitrobenzoyl}benzoic acid
Page last updated: 2024-12-09

2-{4-[(2-aminophenyl)thio]-3-nitrobenzoyl}benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2797589
CHEMBL ID1540870
CHEBI ID183690
SCHEMBL ID24704031

Synonyms (17)

Synonym
2-{4-[(2-aminophenyl)thio]-3-nitrobenzoyl}benzoic acid
smr000455765
MLS000849747 ,
MAYBRIDGE1_000828 ,
HMS543N14
2-[4-(2-aminophenyl)sulfanyl-3-nitrobenzoyl]benzoic acid
2-[4-(2-aminophenyl)sulanyl-3-nitrobenzoyl]benzoic acid
CHEBI:183690
HMS2810F13
2-[4-[(2-aminophenyl)thio]-3-nitro-benzoyl]benzoic acid
bdbm54143
2-[4-(2-aminophenyl)sulfanyl-3-nitro-phenyl]carbonylbenzoic acid
2-[[4-[(2-aminophenyl)thio]-3-nitrophenyl]-oxomethyl]benzoic acid
cid_2797589
CHEMBL1540870
CCG-233992
SCHEMBL24704031
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency70.79460.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.10000.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
hypothetical protein, conservedTrypanosoma bruceiPotency19.95260.223911.245135.4813AID624173
regulator of G-protein signaling 4Homo sapiens (human)Potency25.11890.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency19.95260.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.19950.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
M1-family alanyl aminopeptidasePlasmodium falciparum 3D7IC50 (µMol)98.94002.600048.1803128.9800AID1445
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1705531Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 20 hrs by CLSI based-broth microdilution method2020European journal of medicinal chemistry, Dec-15, Volume: 208Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction.
AID1659001Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658975Antibacterial activity against Streptococcus agalactiae ATCC 12386 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658973Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1659003Antibacterial activity against Escherichia coli ATCC 25922 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658969Antibacterial activity against Enterococcus faecalis ATCC 19433 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658974Antibacterial activity against Streptococcus pyogenes ATCC 19615 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658971Antibacterial activity against Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1659002Antibacterial activity against Enterobacter cloacae ATCC 13047 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658968Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 16 to 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658999Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658972Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1658970Antibacterial activity against Staphylococcus aureus ATCC 25923 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1659000Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 20 hrs by CLSI based-broth microdilution method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.97 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.2510dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.6620glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
ceftriaxone
[no description available]		2.25101,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
fidaxomicin
Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.		2.2510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.6620cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110